29 research outputs found

    When It Rains, It Pours: Future Climate Extremes and Health

    Get PDF
    Background: The accelerating accumulation of greenhouse gases in the Earth’s atmosphere is changing global environmental conditions in unprecedented and potentially irreversible ways. Climate change poses a host of challenges to the health of populations through complex direct and indirect mechanisms. The direct effects include an increased frequency of heat waves, rising sea levels that threaten low-lying communities, anticipated extremes in the global hydrologic cycle (droughts, floods, and intense storms), and adverse effects on agricultural production and fisheries due to environmental stressors and changes in land use. Indirectly, climate change is anticipated to threaten health by worsening urban air pollution and increasing rates of infectious (particularly waterborne and vector-borne) disease transmission. Objective: To provide a state-of-the-science review on the health consequences of a changing climate. Findings: Environmental public health researchers have concluded that, on balance, adverse health outcomes will dominate under these changed climatic conditions. The number of pathways through which climate change can affect the health of populations makes this environmental health threat one of the largest and most formidable of the new century. Geographic location plays an influential role the potential for adverse health effects caused by climate change, and certain regions and populations are more vulnerable than others to expected health effects. Two kinds of strategies are available for responding to climate change: mitigation policies (which aim to reduce greenhouse gas emissions) and adaptation measures (relating to preparedness for anticipated impacts). Conclusions: To better understand and address the complex nature of health risks posed by climate change, interdisciplinary collaboration is critical. Efforts to move beyond our current reliance on fossil fuels to cleaner, more sustainable energy sources may offer some of the greatest health opportunities in more than a century and cobenefits beyond the health sector. Because the nations least responsible for climate change are most vulnerable to its effects, the challenge to reduce greenhouse gas emissions is not merely technical, but also moral

    Guidelines for Modeling and Reporting Health Effects of Climate Change Mitigation Actions.

    Get PDF
    BACKGROUND: Modeling suggests that climate change mitigation actions can have substantial human health benefits that accrue quickly and locally. Documenting the benefits can help drive more ambitious and health-protective climate change mitigation actions; however, documenting the adverse health effects can help to avoid them. Estimating the health effects of mitigation (HEM) actions can help policy makers prioritize investments based not only on mitigation potential but also on expected health benefits. To date, however, the wide range of incompatible approaches taken to developing and reporting HEM estimates has limited their comparability and usefulness to policymakers. OBJECTIVE: The objective of this effort was to generate guidance for modeling studies on scoping, estimating, and reporting population health effects from climate change mitigation actions. METHODS: An expert panel of HEM researchers was recruited to participate in developing guidance for conducting HEM studies. The primary literature and a synthesis of HEM studies were provided to the panel. Panel members then participated in a modified Delphi exercise to identify areas of consensus regarding HEM estimation. Finally, the panel met to review and discuss consensus findings, resolve remaining differences, and generate guidance regarding conducting HEM studies. RESULTS: The panel generated a checklist of recommendations regarding stakeholder engagement: HEM modeling, including model structure, scope and scale, demographics, time horizons, counterfactuals, health response functions, and metrics; parameterization and reporting; approaches to uncertainty and sensitivity analysis; accounting for policy uptake; and discounting. DISCUSSION: This checklist provides guidance for conducting and reporting HEM estimates to make them more comparable and useful for policymakers. Harmonization of HEM estimates has the potential to lead to advances in and improved synthesis of policy-relevant research that can inform evidence-based decision making and practice. https://doi.org/10.1289/EHP6745

    Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    Get PDF
    Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1ÎČ, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1ÎČ innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

    Collaborative approaches to account for the health costs of climate-sensitive events

    No full text
    Not applicable for short communications

    Evaluating responses to health-related messages about the financial costs of climate change

    No full text
    Introduction: Science communication research has increasingly explored what factors shape public opinion around climate change policies. The public health consequences of climate change are becoming an increasingly prominent focus of research and policy, and prior research has identified the importance of health messaging for effective risk communication efforts. While prior research on communication appeals that highlight the impact of climate change on public health has shown promise, evidence around the effectiveness of such appeals remains thin, especially around health-related financial costs related to climate hazards. Materials: We explore how social media messages that describe the ramifications of climate-related health problems may influence support for climate change policies. We fielded an experiment embedded in an online survey of 2,859 English-speaking U.S. adults to understand how health-cost climate messaging may have a differential impact on distinct segments of the public. Treatment groups read a hypothetical social media post about how a failure to invest in climate change mitigation and adaptation may result in financial burdens from either damaged property or healthcare costs due to worsening climate hazards quantified at either a national or household scale. Following exposure to treatment stimuli, respondents were asked to state to what extent they perceived climate change to be a threat to the US, supported policy responses, and supported federal investments in mitigation and adaptation. Results: While all messaging conditions were associated with significantly higher perceptions that climate change poses a threat, no differences were observed when comparing across the health- versus property-related economic damage messages. Conclusion: Communication of costs on a per household basis was associated with significantly higher perceptions that climate change is a threat compared to messages that emphasized costs at a national level

    Air-quality-related health impacts from climate change and from adaptation of cooling demand for buildings in the eastern United States: An interdisciplinary modeling study

    No full text
    <div><p>Background</p><p>Climate change negatively impacts human health through heat stress and exposure to worsened air pollution, amongst other pathways. Indoor use of air conditioning can be an effective strategy to reduce heat exposure. However, increased air conditioning use increases emissions of air pollutants from power plants, in turn worsening air quality and human health impacts. We used an interdisciplinary linked model system to quantify the impacts of heat-driven adaptation through building cooling demand on air-quality-related health outcomes in a representative mid-century climate scenario.</p><p>Methods and findings</p><p>We used a modeling system that included downscaling historical and future climate data with the Weather Research and Forecasting (WRF) model, simulating building electricity demand using the Regional Building Energy Simulation System (RBESS), simulating power sector production and emissions using MyPower, simulating ambient air quality using the Community Multiscale Air Quality (CMAQ) model, and calculating the incidence of adverse health outcomes using the Environmental Benefits Mapping and Analysis Program (BenMAP). We performed simulations for a representative present-day climate scenario and 2 representative mid-century climate scenarios, with and without exacerbated power sector emissions from adaptation in building energy use. We find that by mid-century, climate change alone can increase fine particulate matter (PM<sub>2.5</sub>) concentrations by 58.6% (2.50 ÎŒg/m<sup>3</sup>) and ozone (O<sub>3</sub>) by 14.9% (8.06 parts per billion by volume [ppbv]) for the month of July. A larger change is found when comparing the present day to the combined impact of climate change and increased building energy use, where PM<sub>2.5</sub> increases 61.1% (2.60 ÎŒg/m<sup>3</sup>) and O<sub>3</sub> increases 15.9% (8.64 ppbv). Therefore, 3.8% of the total increase in PM<sub>2.5</sub> and 6.7% of the total increase in O<sub>3</sub> is attributable to adaptive behavior (extra air conditioning use). Health impacts assessment finds that for a mid-century climate change scenario (with adaptation), annual PM<sub>2.5</sub>-related adult mortality increases by 13,547 deaths (14 concentration–response functions with mean incidence range of 1,320 to 26,481, approximately US126billioncost)andannualO<sub>3</sub>−relatedadultmortalityincreasesby3,514deaths(3functionswithmeanincidencerangeof2,175to4,920,approximatelyUS126 billion cost) and annual O<sub>3</sub>-related adult mortality increases by 3,514 deaths (3 functions with mean incidence range of 2,175 to 4,920, approximately US32.5 billion cost), calculated as a 3-month summer estimate based on July modeling. Air conditioning adaptation accounts for 654 (range of 87 to 1,245) of the PM<sub>2.5</sub>-related deaths (approximately US6billioncost,a4.86 billion cost, a 4.8% increase above climate change impacts alone) and 315 (range of 198 to 438) of the O<sub>3</sub>-related deaths (approximately US3 billion cost, an 8.7% increase above climate change impacts alone). Limitations of this study include modeling only a single month, based on 1 model-year of future climate simulations. As a result, we do not project the future, but rather describe the potential damages from interactions arising between climate, energy use, and air quality.</p><p>Conclusions</p><p>This study examines the contribution of future air-pollution-related health damages that are caused by the power sector through heat-driven air conditioning adaptation in buildings. Results show that without intervention, approximately 5%–9% of exacerbated air-pollution-related mortality will be due to increases in power sector emissions from heat-driven building electricity demand. This analysis highlights the need for cleaner energy sources, energy efficiency, and energy conservation to meet our growing dependence on building cooling systems and simultaneously mitigate climate change.</p></div

    The mortality impacts of adaptation due to air pollution.

    No full text
    <p>Shown is the air-pollution-related mortality increase due to adaptation (the mid-century adaptation scenario minus the mid-century climate-only scenario) for (a) PM<sub>2.5</sub> as taken from the Expert F concentration–response function (the median function), (b) O<sub>3</sub> based on Levy et al. [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002599#pmed.1002599.ref097" target="_blank">97</a>] using maximum daily 1-hour concentrations, and (c) O<sub>3</sub> based on Levy et al. [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002599#pmed.1002599.ref097" target="_blank">97</a>] using maximum daily 8-hour average concentrations.</p
    corecore